financetom
Business
financetom
/
Business
/
Economic Headwinds Impact Grainger's Top Line: Q2 Results Mixed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Economic Headwinds Impact Grainger's Top Line: Q2 Results Mixed
Aug 1, 2024 7:23 AM

W.W. Grainger Inc shares are trading lower after it reported second-quarter 2024 results.

Sales of $4.312 billion, up 3.1% Y/Y, missed the consensus of $4.348 billion.

In Q2 2024, High-Touch Solutions – N.A. saw a 3.1% Y/Y increase in sales, or 3.7% in constant currency, driven by higher volumes and gains across most markets.

Endless Assortment segment sales rose 3.3%, or 11.7% in constant currency, thanks to strong core B2B growth at Zoro and MonotaRO.

Adjusted gross profit increased 3.0% Y/Y to $1.694 billion, with a margin remained flat Y/Y at 39.3%. Adjusted operating profit increased 0.6% Y/Y to $665 million, with the margin at 15.4%, down 40 basis points Y/Y.

Adjusted EPS rose 5.2% Y/Y to $9.76, beating the consensus of $9.58.

In Q2 2024, the company generated $411 million in operating cash flow, with strong net earnings tempered by unfavorable working capital.

During the quarter, the company returned $345 million to shareholders via dividends and share repurchases.

Outlook: Grainger narrows FY24 net sales outlook to $17 billion-$17.3 billion (from  $17.2 billion-$17.7 billion) vs. $17.37 billion estimate and EPS of $38.00-$39.50 (from $38.00-$40.50) vs. street view of $39.15.

The company now projects buyback of $1 billion – $1.2 billion in FY24 (vs. $900 million – $1.1 billion earlier).

Investors can gain exposure to the stock via Franklin Disruptive Commerce ETF and SMI 3Fourteen Full-Cycle Trend ETF ( FCTE ) .

Price Action: GWW shares are down 5.30% at $925.00 premarket at the last check Thursday.

Now Read:

Meta Platforms Stock Is Rallying Thursday – What’s Going On?

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UnitedHealth taps Medicare head as CEO of insurance business
UnitedHealth taps Medicare head as CEO of insurance business
Jan 23, 2025
Jan 23 (Reuters) - UnitedHealth Group ( UNH ) said on Thursday it has appointed Tim Noel, the head of its Medicare business, to replace late CEO Brian Thompson as the head of its insurance unit. (Reporting by Mariam Sunny in Bengaluru) ...
General Motors Shares Are Rising Today: What's Going On?
General Motors Shares Are Rising Today: What's Going On?
Jan 23, 2025
General Motors Co. ( GM ) shares are trading higher Thursday on reports the company and Hyundai are forging an EV partnership for North America. What To Know: Hyundai has confirmed ongoing talks to supply commercial electric vehicles to GM as part of a broader collaboration that includes parts procurement and passenger vehicle cooperation, according to Reuters. The companies reportedly...
Tiziana Life Sciences' Foralumab Demonstrates Motor Function Improvement in Preclinical Spinal Cord Injury Studies
Tiziana Life Sciences' Foralumab Demonstrates Motor Function Improvement in Preclinical Spinal Cord Injury Studies
Jan 23, 2025
03:30 PM EST, 01/23/2025 (MT Newswires) -- Tiziana Life Sciences ( TLSA ) said Thursday that preclinical studies of foralumab, a nasal anti-CD3 monoclonal antibody, in traumatic spinal cord injury showed notable improvements in motor functions. The company said it is also evaluating the drug candidate in a phase 2a study for patients with non-active secondary progressive multiple sclerosis. Shares...
Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing
Apellis Pharmaceuticals Insider Sold Shares Worth $412,296, According to a Recent SEC Filing
Jan 23, 2025
03:32 PM EST, 01/23/2025 (MT Newswires) -- Cedric Francois, Director, Chief Executive Officer, on January 22, 2025, sold 13,551 shares in Apellis Pharmaceuticals ( APLS ) for $412,296. Following the Form 4 filing with the SEC, Francois has control over a total of 1,957,941 shares of the company, with 418,519 shares held directly and 1,539,422 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1492422/000112760225001837/xslF345X05/form4.xml...
Copyright 2023-2026 - www.financetom.com All Rights Reserved